47 results about "Pulmonary tuberculosis" patented technology

The invention discloses an intelligent pulmonary tuberculosis recognition method and system based on image data, and relates to the technical field of image recognition, and the method comprises the steps: collecting and preprocessing conventional inspection data from different medical devices, and forming a standardized data set; extracting features from the standardized data set by using a deep learning model, and positioning a suspected focus area; based on the positioned suspected focus area, constructing a personalized risk assessment model, and generating a risk score; performing focus quantitative analysis based on the risk score, and generating a diagnosis report; the diagnosis report is applied to clinical practice, and a personalized diagnosis and treatment plan is made; according to the method, the personalized risk assessment model is constructed based on the positioned suspected focus area, the risk score is generated, and quantitative assessment of the health condition of the patient is realized.

The invention discloses an intelligent pulmonary tuberculosis detection method and system based on images and clinical data, and belongs to the field of medicines.The method comprises the steps that S1, high-resolution chest X-ray images and clinical data such as serum C-reactive protein concentration, erythrocyte sedimentation value, erythrocyte distribution width and body temperature are collected; s2, performing non-linear contrast enhancement on the image, and extracting lung gate texture, lung field transparency and cavity edge features; s3, fusing the image and the clinical features through a graph attention mechanism, and generating a high-dimensional fusion vector; s4, risk grade discrimination is carried out through a multi-scale residual mapping network, and five-grade labels are output; and S5, optimizing the model by utilizing the pathology definite diagnosis sample in combination with the cross entropy and the center loss. The method has the beneficial effects that accurate grading evaluation of the pulmonary tuberculosis risk is realized, and the accuracy of early screening and the clinical interpretability of the model are improved.

The invention relates to exosome-coated dendrimer nanogel co-loaded with gold nanoparticles and antibiotics as well as a preparation method and application of the exosome-coated dendrimer nanogel, the dendrimer nanogel is taken as a carrier, the gold nanoparticles and drugs are co-loaded in the carrier, and the surface of the carrier is coated with exosome. The operation condition is simple, purification is easy, the bioavailability of antibiotics can be improved, targeted delivery and responsive release of the medicine at the focus position are achieved, and the good application prospect in pulmonary tuberculosis treatment is achieved.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The application belongs to the technical field of biotechnology, and particularly relates to a biomarker for differential diagnosis of severe pulmonary tuberculosis. It is found that the XO content in blood of a severe pulmonary tuberculosis patient is significantly lower than that of a non-severe subject, the area (AUC) under the ROC curve in a screening test is 0.898, and the area (AUC) under the ROC curve in a verification test is 0.904. The application is helpful for early assessment of the condition of a pulmonary tuberculosis patient, and provides a basis for early intervention and comprehensive treatment of severe patients.

A molecular marker for drug resistance in Mycobacterium tuberculosis, a reagent kit for detecting drug resistance in Mycobacterium tuberculosis, and a detection method thereof, comprising detecting nonsynonymous mutations at specific gene loci in the pncA gene, rpsA gene, or panD gene, or detecting mutations at specific amino acid loci in the pncA protein, rpsA protein, or panD protein, can help doctors select the most suitable treatment plan for pulmonary tuberculosis, improve the success rate of treatment, reduce the infection and spread of pulmonary tuberculosis, thereby protecting patients and public health.

The utility model discloses an infection department pulmonary tuberculosis protection device relates to medical instrument technical field, including transparent face guard, the right side of transparent face guard front and back part is all fixedly connected with connecting plate, the right side of two connecting plate upper part is all fixedly connected with arc support plate, the right side of two arc support plate is all fixedly connected with fixed bandage, the inner wall fixedly connected with protection subassembly of transparent face guard, the opposite surface fixedly connected with two connecting plates of protection subassembly's outer wall respectively. The utility model discloses an infection department pulmonary tuberculosis protection device, through the effect of protection clothes no.

The utility model relates to the field of medical equipment, and discloses a sputum excretion device for pulmonary tuberculosis nursing, which comprises a sputum excretion device main body, one side of the sputum excretion device main body is fixedly connected with a base, the top of the base is provided with a sputum suction tank, the outer side of the sputum suction tank is provided with a connecting assembly I, and the top of the base is provided with a fixing assembly. A sealing cover is arranged at the top of the sputum suction tank, a second connecting assembly is arranged at the top of the sealing cover and comprises an inlet pipe and an air outlet pipe, the outer side of the inlet pipe and the outer side of the air outlet pipe are both fixedly connected to the interior of the sealing cover, a first groove is formed in the outer side of the inlet pipe, and a second groove is formed in the outer side of the air outlet pipe. According to the sputum suction tube, the convex rings are arranged in the sputum suction tube and the air suction tube, when the sputum suction tube and the air suction tube are connected with the corresponding connectors in an inserted mode, the convex rings in the sputum suction tube and the air suction tube can be clamped in the grooves in the outer sides of the connectors, the air tightness of the connecting positions of the sputum suction tube and the air suction tube is good through interference fit, and the poor sputum suction effect caused by air leakage is avoided.

The invention belongs to the technical field of bioengineering, and particularly provides application of a JNK inhibitor in preparation of drugs for preventing and / or relieving and / or treating pulmonary tuberculosis aiming at the problem that whether the existing JNK inhibitor SP600125 can inhibit BNIP3-mediated mitochondrial autophagy and further exert the ROS bactericidal effect is unknown. And the JNK inhibitor is an SP600125 JNK inhibitor. The JNK inhibitor is used for inhibiting mitochondrial autophagy in the BCG infected macrophages. The JNK inhibitor reduces the up-regulation of BNIP3 and LC3B caused by BCG infection. It is found through the application that when the concentration of the JNK inhibitor reaches 15 umol / L, remarkable cytotoxicity begins to appear, and compared with a control group, the cell survival rate is remarkably decreased. The SP600125 can be used for inhibiting mitochondrial autophagy and down-regulating the expression of BNIP3 and LC3B. Inhibition of JNK expression can inhibit survival of Mtb in RAW264.7 macrophages, and a new thought and direction are provided for treatment of tuberculosis.

The present application relates to a method for increasing the adhesion of a slide, belonging to the technical field of biological medicine, to solve at least one of the problems in the prior art, such as poor adhesion of mycobacterium tuberculosis on the slide, easy to drop the slide in subsequent operation, serious loss of mycobacterium tuberculosis, and influence on the diagnosis rate of pulmonary tuberculosis. The dextromethorphan hydrobromide tablets and the flaxseed gum can generate a high molecular water-soluble polymer with strong positive charge adhesion under the action of a catalyst, that is, the binder described in the present application. Since mycobacterium tuberculosis is the pathogen causing tuberculosis, its surface has a large number of negative charges. Once the mycobacterium tuberculosis with negative charges on the surface contacts the binder containing a large number of positive charges, the surface of the mycobacterium tuberculosis will be quickly wrapped by the binder, forming a firm adhesion layer, and the problem of easy dropping of the slide will not occur during staining and subsequent detection.

The application discloses a kind of pulmonary tuberculosis focus detection method, system and storage medium based on shared feature map, obtains CT image sample;Improvement is carried out based on YOLO neural network model, PA module is used in main network to extract the feature of small pulmonary tuberculosis in CT image;Neck network adds shared feature map CAB and C2f-RFCBAMConv module uses shared feature map to obtain multiple feature information, to obtain the final pulmonary tuberculosis focus feature;And the way of combining NWD and WIou is added to improve the weighting mechanism to adjust the influence degree of different samples. The trained optimized network model is used for focus detection of CT image sample, in order to meet the high demand of detecting small pulmonary tuberculosis and multi-feature information target, the detection sensitivity and positioning accuracy of pulmonary tuberculosis focus are significantly improved, the misdiagnosis rate is effectively reduced, and effective support is provided for clinical diagnosis.

The application provides a method for evaluating the risk of tuberculosis under the combined exposure of extreme weather and air pollution, comprising the steps of: obtaining meteorological data, air pollution data and tuberculosis incidence data of a target area within a target period; identifying extreme weather events based on the meteorological data, identifying air pollution events based on the air pollution data, and identifying combined exposure events based on the meteorological data and the air pollution data, wherein the combined exposure events are combinations of the extreme weather events and the air pollution events that occur within a time interval less than a preset threshold and are spatially co-located; based on the spatial co-location, constructing a regression model with the number of cases in the tuberculosis incidence data as the dependent variable and whether the combined exposure event occurs as the binary explanatory variable, and evaluating the influence of the combined exposure event on the risk of tuberculosis. The application realizes high-precision quantitative evaluation of the risk of tuberculosis under the combined exposure of extreme weather and air pollution, and provides a scientific basis for early warning and precise prevention and control.

1. Name of the product in this design: Packaging Box (Tuberculosis Detection Reagent). 2. Purpose of this design: To hold tuberculosis test reagents. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application discloses a mycobacterium membrane protein MmpL3 inhibitor, a pharmaceutical composition thereof and application. The application provides a compound as shown in formula I, a pharmaceutically acceptable salt or a stereoisomer thereof. The compound of the application has a good inhibiting effect on Mycobacterium tuberculosis, and has a good application prospect in treating various diseases related to mycobacterium.

The invention relates to a pulmonary tuberculosis CT image recognition method and system and electronic equipment. The method comprises the following steps: acquiring lung CT image data; the method comprises the following steps: preprocessing lung CT image data, inputting the preprocessed lung CT image data into a backbone network to extract multi-scale features, and obtaining three feature maps output at different depths; three feature maps output at different depths are input into a feature diffusion pyramid module, and after two-stage multi-scale feature focusing and feature diffusion are performed in sequence, corresponding diffusion fusion features, semantic enhancement features and detail enhancement features are output; and taking the diffusion fusion feature, the semantic enhancement feature and the detail enhancement feature as input of a target detection head to obtain a pulmonary tuberculosis image detection result. According to the method, features of different depths are extracted, low-level detail information and high-level semantic information are integrated through two-level multi-scale feature focusing and feature diffusion, and the target detection capability in a feature fuzzy and high-noise region is effectively improved.

The application relates to an active pulmonary tuberculosis marker and application thereof, the active pulmonary tuberculosis marker is PCBP1, the expression of the PCBP1 in peripheral blood mononuclear cells of an active pulmonary tuberculosis patient is obviously down-regulated, the down-regulated PCBP1 has certain significance for diagnosis of the active pulmonary tuberculosis patient. Moreover, the expression amount of the PCBP1 in the APTB patient is detected by using an RT-qPCR and western blot method, the disease can be diagnosed, and then the active pulmonary tuberculosis diagnosis reagent can be prepared. The application discloses that the PCBP1 can be used as the active pulmonary tuberculosis marker for the first time, and provides a new direction for clinical diagnosis of the active pulmonary tuberculosis.

The application discloses a kind of tuberculosis CT image classification method, system, equipment and storage medium, including based on Mask RCNN model constructs initial tuberculosis CT image classification model: the labeled tuberculosis CT image dataset is input initial tuberculosis CT image classification model and is trained, obtains the multi-task loss value of first RPN network, first predicted multi-task loss value and first tuberculosis CT image classification model, if the multi-task loss value of first RPN network and first predicted multi-task loss value reaches preset value, first tuberculosis CT image classification model is regarded as the tuberculosis CT image classification model of well-trained;If not reach preset value, then according to the multi-task loss value of first RPN network and first predicted multi-task loss value updates first training parameter, in turn, until the tuberculosis CT image classification result of image to be predicted is obtained, improve the classification efficiency and classification accuracy of tuberculosis infectivity.

The invention discloses a model construction method for pulmonary tuberculosis transmission prevention and control and patient medical treatment strategy optimization, and belongs to the technical field of infectious disease models. Aiming at the problem that quantitative optimization of patient medical treatment strategies and accurate simulation of propagation dynamics are lacked in existing pulmonary tuberculosis prevention and control, an SEIHR propagation dynamics model including susceptible persons, latent persons, patients, medical treatment persons and rehabilitation persons is constructed; introducing a control variable into the kinetic model, and constructing an optimal control model for the propagation of the pulmonary tuberculosis in the crowd; setting a target function to obtain an optimal control variable; the control variables are combined according to single-term control and multi-term control, and an optimal control strategy is obtained by comparing combinations of different controls. Results show that through cooperative control of the three measures, the number of infected people can be reduced as soon as possible, the rehabilitation rate can be maximized, and when medical resources are insufficient, an isolation and cure combination is recommended. The invention provides a quantitative basis for scientific formulation of a pulmonary tuberculosis prevention and control strategy.

The application discloses a pulmonary tuberculosis morbidity risk prediction system and application, and is suitable for pulmonary tuberculosis morbidity risk assessment of the elderly. Baseline data of the elderly population meeting the standard are collected, pretreated through cleaning, resampling, coding standardization and the like, a plurality of machine learning models are constructed and performance is compared, a random forest is screened out as an optimal algorithm, 11 core factors of gender, educational level, residence, body mass index BMI, age, occupation, smoking status, complication condition, drinking status, marital status and previous tuberculosis history are selected to construct a model, internal and external verification is carried out, and the model AUC reaches 0.872 and 0.812 respectively, and the calibration degree is good. A prediction system including data collection, analysis and the like units is built based on the model, a Web application tool of a Shiny framework is developed, interactive input of risk factors is realized, morbidity probability is automatically calculated, and three-level risk grading is realized. The application is simple in operation, accurate in prediction, can improve the active screening efficiency of community elderly pulmonary tuberculosis, and provides a scientific tool for accurate prevention and control.

The invention discloses a household aerosol inhalation device for treating pulmonary tuberculosis, and relates to the technical field of medical instruments. The device comprises an atomization assembly, an oxygen supply assembly and a breathing assembly. An atomization main body and a control panel integrated with a vital sign monitoring module are arranged in the atomization assembly; the oxygen supply assembly is detachably arranged on the side wall of the atomization assembly and used for providing and adjusting oxygen. The breathing assembly is simultaneously connected with the atomization pipeline and the oxygen supply pipeline through a connecting seat, and a one-way valve and an inward-concave structure are arranged in the connecting seat and used for guiding inhaled mixed gas and guiding exhaled gas to enter a treatment tank at the bottom end of the mask to be treated. According to the invention, the synchronization of atomization administration and continuous oxygen supply is realized, the bacteria-containing aerosol is filtered from the source through the treatment tank, and the vital sign monitoring function is combined, so that the problems that oxygen therapy needs to be interrupted, the cross infection risk is high and the state of a patient cannot be monitored in real time in traditional treatment are effectively solved, and the safety and effectiveness of treatment are remarkably improved.

The invention relates to a traditional Chinese medicine preparation for treating hydropneumosis and leg and foot edema and a preparation method thereof. The preparation is prepared from 15g of pinellia ternate stems and leaves, 25g of lysimachia christinae hance stems and leaves, 75g of wild pineapple fruits, 3g of fresh ginger and 3g of liquorice. The preparation method comprises the following steps: adding 1500g of water into the medicinal materials, soaking for 10 minutes, boiling with big fire, decocting with small fire until the medicine liquid is concentrated to 500g, filtering, repeatedly decocting once, and combining the two filtrates to obtain 1000g of medicine juice. The medicine juice is taken three times a day in two days, and clinical observation shows that after a patient continuously takes the medicine juice for 4 days, the effusion reduction rate is remarkable. The preparation has the effects of inducing diuresis to reduce edema and promoting effusion discharge, has no obvious toxic or side effect, and is suitable for hydropneumosis and lower limb edema caused by pneumonia, pulmonary tuberculosis, lupus erythematosus and other diseases.

The invention discloses application of a reagent for detecting the content or expression level of TIPE2 in a sample in preparation of a reagent for diagnosing and / or predicting active tuberculosis. In the application, the sample comprises a blood sample. According to the application, the TIPE2 in a blood sample is used as the biomarker for detecting the active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of the TIPE2 in whole blood has good sensitivity and specificity on active tuberculosis diagnosis.

The present application provides siRNA delivery nanomaterials targeting M2 macrophages, which are mannosylated bovine serum albumin nanoparticles encapsulating siRNA interfering with KLK12. The mannose coating of the materials of the present application can provide targeting effect on M2 macrophages, and the siRNA released after endocytosis of the materials can silence the expression of KLK12 and its downstream MMPs genes, reduce the degradation of collagen fibers in lung tissues, thereby controlling the number and volume of pulmonary tuberculosis granulomas, preventing the occurrence of active tuberculosis, and providing a new option for the treatment of tuberculosis.

This invention discloses a respiratory assist device for tuberculosis patients based on motion status, belonging to the field of medical devices. It includes a respiratory assist device with a binding component on one side for securing it to the user's waist. A self-displacement component is mounted on a mounting frame within the binding component, and the respiratory assist device is connected to a sliding frame within the self-displacement component via a connecting component. This application utilizes the binding component to stably secure the entire device to the user's waist, providing a fixed mounting base for the respiratory assist device and ensuring it will not easily detach or shift during user activity. Then, the self-displacement component moves the respiratory assist device mounted on the sliding frame, ultimately precisely adjusting it to a position on the user's lower back. This position better matches the user's breathing rhythm and reduces interference with daily activities.

The invention provides an application of a glycerol kinase gene and an aspartate beta-hydroxylase domain 2 gene in pulmonary tuberculosis disease risk assessment. The invention provides a method for carrying out pulmonary tuberculosis disease risk grouping or auxiliary grouping on subjects. The method comprises the following steps: receiving gene expression quantity data in blood samples of the subjects; carrying out pulmonary tuberculosis disease risk grouping or auxiliary grouping on the subjects according to the gene expression quantity data; the gene at least comprises a glycerol kinase gene (GK gene). The method provided by the invention can be used for evaluating or assisting in evaluating the pulmonary tuberculosis disease risk of the subject, improves the accuracy of risk evaluation, and has a relatively high clinical application value.

The application discloses an AI-based medical image X-ray tuberculosis medical information management system, which comprises an image data analysis module, a digital model construction module, a particle dynamic simulation module, a feature focusing extraction module and an auxiliary evaluation output module. The system analyzes target medical images to obtain anatomical structures, respiratory phase states and active lesion areas as a source of dissemination. Accordingly, a personalized lung model is constructed and model parameters including simulated airways and airflow are generated. Then, the diffusion and deposition of biological particles in the bidirectional airflow are simulated from the source of dissemination, and probability distribution data of the dissemination risk are generated. With the data as spatial attention weights, the image is subjected to feature extraction, focusing on detecting small abnormalities in high-risk areas, and generating small lesion detection results. Finally, the probability distribution data and the detection results are fused to output a visual evaluation report. The application significantly improves the recognition ability of small lesions by simulating the disease dissemination mechanism to guide detection.

This invention provides a biomarker for the differential diagnosis of active pulmonary tuberculosis. The biomarker is TRANCE protein. The AUC value of this biomarker for the differential diagnosis of patients with active pulmonary tuberculosis is >0.8, indicating that the biomarker screened by this invention has high diagnostic efficacy for active pulmonary tuberculosis.

The invention discloses a pill formula for treating pulmonary tuberculosis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 2-5 parts of red ginseng, 2-5 parts of American ginseng, 2-5 parts of astragalus membranaceus, 2-5 parts of rhizoma polygonati, 2 parts of codonopsis pilosula, 2 parts of radix ophiopogonis, 2 parts of human placenta, 2 parts of bletilla striata, 2 parts of radix stemonae, 2 parts of radix ranunculi ternati, 1-5 parts of schisandra chinensis, 1-5 parts of sanguisorba officinalis, 1-5 parts of tortoise shell, 1-5 parts of scandent hop, 1 part of scorpion, 1 part of Chinese polyphaga, 1 part of centipede, 1 part of golden cypress, 1 part of cyrtomium fortunei and 1 part of liquorice. Through verification, the pill for treating pulmonary tuberculosis is safe to use and has no adverse side effect. The curative effect is obvious and stable. The traditional Chinese medicine has the advantages of fast effect taking and short treatment course, and can be taken for at least 6 months in general treatment of pulmonary tuberculosis with western medicine, and can be taken for only 3 months to completely cure the pulmonary tuberculosis with anti-tuberculosis medicine for 9 months. As long as the pulmonary tuberculosis is determined, the patient does not need to see a doctor personally and can be easily cured at home according to the description. The treatment cost is lower than that of other therapies.

The invention belongs to the technical field of medicines, and discloses a substituted thiophene imide ethyl ester compound as well as a preparation method and application thereof. Specifically, the present invention relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound of the present invention, in which R1, R2 and Ar are as described in the specification. The invention aims to prepare a novel DprE1 inhibitor which has good inhibitory activity on both a DprE1 wild type and a DprE1 mutant type, has anti-mycobacterium tuberculosis activity, particularly has a better inhibitory effect on drug-resistant mycobacterium tuberculosis, has an obviously weakened inhibitory effect on liver drug enzyme CYP 2C9, is low in cytotoxicity, and can be used for preparing a novel DprE1 inhibitor. The compound has excellent anti-tuberculosis activity in macrophages, can be used for treatment or prophylactic treatment of infectious diseases caused by bacteria, especially tuberculosis (TB) diseases caused by mycobacterium tuberculosis, and can also be used for overcoming the problems of mycobacterium tuberculosis DprE1 target protein mutation and drug-resistant mycobacterium tuberculosis infection.

Provided in the present invention is a biomarker for the differential diagnosis of active pulmonary tuberculosis, wherein the biomarker is a TRANCE protein, and has an AUC value of >0.8 for the differential diagnosis of patients with active pulmonary tuberculosis, indicating that the biomarker screened in the present invention has a relatively high diagnostic efficacy on active pulmonary tuberculosis.